Establishment of an isogenic human colon tumor model for NQO1 gene expression: Application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo

Molecular Pharmacology

Volumn 58, Issue 5, 2000, Pages 1146-1155

  Sharp, Swee Y ^a   Kelland, Lloyd R ^a   Valenti, Melanie R ^a   Brunton, Lisa A ^a   Hobbs, Steve ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIAZIRIDINYL 3 (HYDROXYMETHYL) 6 METHYL 1,4 BENZOQUINONE; 2,5 DIAZIRIDINYL 3 HYDROXYMETHYL 6 METHYL 1,4 BENZOQUINONE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; DIAZIQUONE DERIVATIVE; DICOUMAROL; ELONGATION FACTOR 1; EO 2; EO 7; GENE PRODUCT; MENADIONE; MITOMYCIN; PROTEIN NQO1; PUROMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RUFOCROMOMYCIN; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON TUMOR; CONTROLLED STUDY; DRUG ACTIVATION; DRUG POTENTIATION; ENZYME SUBSTRATE; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR CELL CULTURE; TUMOR MODEL;

EID: 0033785989     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.58.5.1146     Document Type: Article

References (67)

1. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones
2. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9
3. Indolequinone antitumor agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:Quinone Oxidoreductase, and in vitro cytotoxicity
4. Role of NAD(P)H:Quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin
5. NAD(P)H quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines
6. NAD(P)H:Quinone oxidoreductase 1 (DT-diaphorase) expression in normal and tumor tissues
7. Bioreductive agents: A clinical update
8. Catalytic properties of NAD(P)H:Quinone accepter oxidoreductase: Study involving mouse, rat, human and mouse-rat chimeric enzymes
9. EO9: Relationship between DT-diaphorase levels and response in vitro and in vivo
10. Antitumour activity of the novel bioreductive MeDZQ against human non-small cell lung cancer xenografts
11. Enzymology of mitomycin C metabolic activation in tumour tissue: Implications for enzyme-directed bioreductive drug development
12. DT-diaphorase: A historical review
13. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes
14. Reduction of 3-amino-1,2,4-benzotriazine-1, 4-di-N-oxide (tirapazamine; WIN 59075; SR 4233) to a DNA-damaging species: A direct role for NADPH:Cytochrome P450 oxidoreductase
15. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9
16. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity
17. Expression of human NAD(P)H:Quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: Effect on the toxicity of antitumor quinones
18. Enhancement of xanthine dehydrogenase mediated mitomycin C metabolism by dicumarol
19. Decreased NADPH:Cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions
20. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1α promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins
21. Potentiation of mitomycin C and porfiromycin toxicity to Chinese hamster ovary (CHO) cells by overexpression of DT-diaphorase (DTD) cDNA
22. 5 reductase
23. Human NAD(P)H:Quinone oxidoreductase (NQO1) gene structure and induction by dioxin
24. Jun and Fos regulation of NAD(P)H:Quinone oxidoreductase gene expression
25. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
26. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy
27. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs
28. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice
29. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: Circumvention studies using novel platinum (II) and (IV) ammine/amine complexes
30. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relationship to the response of lung tumor xenografts to mitomycin C
31. 5 reductase in human lung and breast tumours
32. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines
33. Relevance of DT-diaphorase activity to mitomycin C (MMC) efficacy on human cancer cells: Differences in in vitro and in rive systems
34. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR4233)
35. Enzymology of tirapazamine metabolism: A review
36. Overexpression of human NADPH:Cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069
37. Correlations of DT-diaphorase expression with cell sensitivity data obtained from the NCI human tumor cell line panel
38. Bioreductive activation of a series of analogs of 5-Aziridinyl-3-hydroxymethyl 1-methyl-2-[1H-indole-4,7-dione] prop-β-en-α-ol (EO9) by human DT-diaphorase
39. DT-diaphorase protects cells from hypoxic cytotoxicity of indoloquinone EO9
40. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity
41. DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis
42. Initial characterisation of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxia cytotoxin 3-amino-1,2,4-benzotriazine-1,4 di-N-oxide (tirapazamine, SR 4233, WIN 59075)
43. DT-diaphorase and cancer chemotherapy
44. Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: Quinone-acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells
45. NAD(P)H:menadione oxidoreductase. Novel purification of enzyme, cDNA and complete amino acid sequence, and gene regulation
46. The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase?
47. Enzymology of bioreductive drug activation
48. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C
49. Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumour tissue: Effects of cigarette smoking and alcohol
50. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines
51. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): Role of diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells
52. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells
53. DT-diaphorase activity in normal and neoplastic human tissues: An indicater for sensitivity to bioreductive agents?
54. Bioreductive drugs into the next millennium
55. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes: A study of the implications of oxidative stress in intact cells
56. NAD)P)H:Quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity
57. Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Final results from the International phase III CATAPULT 1 trial
58. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas
59. The role of NAD(P)H:Quinone reductase (EC 1.6.99.2, DT-Diapharose) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9
60. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR4233) by mouse liver
61. Enzymology of the reductive bioactivation of SR 4233: A novel benzotriazine di-N-oxide hypoxic cell cytotoxin
62. Modulation of the toxicity and macromolecular binding of benzene metabolites by NAD(P)H:Quinone oxidoreductase in transfected HL-60 cells
63. A new screening system for NAD(P)H:Quinone oxidoreductase (NQO1)-directed antitumor quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent
64. Enzyme-directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase
65. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition)
66. DT-diaphorase: Questionable role in mitomycin C resistance but a target for novel bioreductive drugs?